Eli Lilly and Company (LLY)

LLY (NYSE:Drugs)
$54.14
neg -0.60
-1.10%
Today's Range: 53.89 - 54.50 | LLY Avg Daily Volume: 5,092,700
Last Update: 05/24/13 - 4:00 PM EDT
Volume: 4,936,468
YTD Performance: 10.99%
Open: $54.50
Previous Close: $54.74
52 Week Range: $39.93 - $58.41
Oustanding Shares: 1,126,561,464
Market Cap: 61,870,755,603
6-Month Chart
TheStreet Ratings Grade for LLY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 5 5
Moderate Buy 0 0 0 0
Hold 5 7 7 8
Moderate Sell 1 1 1 1
Strong Sell 3 3 3 2
Mean Rec. 2.74 2.77 2.77 2.64
Latest Dividend: 0.49
Latest Dividend Yield: 3.57%
Dividend Ex-Date: 05/14/13
Price Earnings Ratio: 13.17
Price Earnings Comparisons:
LLY Sector Avg. S&P 500
13.17 13.20 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.87% 34.60% 65.28%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.90 0.04 0.01
Net Income 0.00 0.00 0.00
EPS -6.20 -0.07 -0.02
Earnings for LLY:
EBITDA 6.48B
Revenue 22.60B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $1.00 $0.94 $3.91 $2.75
Number of Analysts 8 7 12 10
High Estimate $1.05 $0.98 $3.96 $2.90
Low Estimate $0.95 $0.87 $3.85 $2.62
Prior Year $0.83 $0.79 $3.39 $3.91
Growth Rate (Year over Year) 21.08% 19.35% 15.39% -29.67%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
SeekingAlpha
SeekingAlpha: Diabetes And Oncology Might Cushion Eli Lilly's Fall Off A Patent Cliff http://t.co/Hc62Vk1PBV $A $QGEN $LLY
53 minutes ago from Seeking Alpha
micenter
micenter: Eli Lilly $LLY Could Break Through $55.64 Resistance Level ( http://t.co/ycc6mjHAhc )
6 hours ago from Marketintelligencecenter.com
SeekingAlpha
SeekingAlpha: Billionaire Jim Simons' Top Dividend Stock Holdings http://t.co/R3e7CmOTSo $AZN $INTC $LLY $LO $PM
7 hours ago from Seeking Alpha
EventsCIAA
EventsCIAA: RT @FiercePharma: Merck, Lilly, Pfizer form top ranks of $1B doc-payments list from FT http://t.co/2QPP9gPS6Z #pharma $MRK $LLY $PFE
9 hours ago from web
megalomaniac
megalomaniac: Fave headline of day: $BI and $LLY launched a diabetes game called "Complications Combat". Not what ppl meant by gamifying health, I think.
10 hours ago from iOS
medstudentrader
medstudentrader: RT @pelias01: 6 Ways You Can Profit From Molecular Diagnostics http://t.co/fP0hRE9Upu $EXAS $GHDX $ILMN $LLY $MYGN $NSPH $QGEN $SQNM
10 hours ago from Twitter for Mac
1gecko2014
1gecko2014: RT @pelias01: 6 Ways You Can Profit From Molecular Diagnostics http://t.co/fP0hRE9Upu $EXAS $GHDX $ILMN $LLY $MYGN $NSPH $QGEN $SQNM
10 hours ago from Twitter for iPhone
pelias01
pelias01: 6 Ways You Can Profit From Molecular Diagnostics http://t.co/fP0hRE9Upu $EXAS $GHDX $ILMN $LLY $MYGN $NSPH $QGEN $SQNM
11 hours ago from Tweet Button
FierceHealth
FierceHealth: RT @FiercePharma: Merck, Lilly, Pfizer form top ranks of $1B doc-payments list from FT http://t.co/2QPP9gPS6Z #pharma $MRK $LLY $PFE
1 day ago from web
FiercePharma
FiercePharma: Merck, Lilly, Pfizer form top ranks of $1B doc-payments list from FT http://t.co/2QPP9gPS6Z #pharma $MRK $LLY $PFE
1 day ago from TweetDeck

bullishEli Lilly numbers raised at Citigroup

Jan 30, 2013 | 7:47 AM EST

Shares of LLY now seen reaching $60, Citigroup said. Estimates also increased as stronger base undervalues Ramucirumab call option. Buy rating. 

Morning Es Trading

By

Bob Byrne

 | Jan 29, 2013 | 8:28 AM EST

Our primary area of interest this morning will be the 1494.50 level.

Blown Away by Transports, Drugs

By

Jim Cramer

 | Jan 10, 2013 | 3:30 PM EST

Not so much by the financials.

bullishEli Lilly rated new Buy at Citigroup

Nov 30, 2012 | 8:23 AM EST

LLY was initiated with a Buy rating, Citigroup said. $55 price target. Sequestration risk to Medicare part D drugs spend small. 

updateCredit Suisse Healthcare Conf.

Nov 15, 2012 | 7:05 AM EST

Credit Suisse Group AG Healthcare Conference

bearishEli Lilly numbers cut at BMO

Oct 26, 2012 | 8:32 AM EDT

Shares of LLY now seen reaching $47, BMO said. Estimates also lowered on cautious outlook on Sola. Market Perform rating. 

Watch Out for the Tightrope

By

Jim Cramer

 | Oct 16, 2012 | 8:20 PM EDT

It’s been a thoroughly boring, commonsense rally.

bullishEli Lilly target boosted at BofA/Merrill

Oct 11, 2012 | 8:20 AM EDT

Shares of LLY now seen reaching $57, according to Bank of America/Merrill Lynch said. Sola should ultimately reach the market for Alzheimer's. Buy rating. 

bullishEli Lilly upgraded at Goldman

Oct 9, 2012 | 7:51 AM EDT

LLY was upgraded from Sell to Neutral, Goldman Sachs said. $54 price target. Sola could reach the market in 3 to 4 years. 

bullishEli Lilly numbers raised at Credit Suisse

Oct 1, 2012 | 8:13 AM EDT

Shares of LLY now seen reaching $54, according to Credit Suisse. Estimates also increased, given higher expected Ramucirumab sales. Outperform rating. 

Columnist Conversation / Market Updates

SPX cash daily chart
By

Carolyn Boroden

 | May 24, 2013 | 3:24 PM EDT
There is no technical damage on the daily chart of $SPX at this point. Actually this decline is only similar to prior d...

Minding Metlife
By

Gary Morrow

 | May 24, 2013 | 3:17 PM EDT
Metlife Inc. became very overbought last week reaching a level not seen in over a year. MET had been in rally mode...
See more »

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.